Category Archives: Biologics/Biosimilars

Rethinking IP in the TPP: Canadian Government Plays Key Role in Suspending Unbalanced Patent and Copyright Rules

Source: http://www.michaelgeist.ca/2017/11/rethinking-ip-in-the-tpp/ Years of disappointment in trade negotiations have left many Canadian intellectual property watchers hoping for the best, but expecting the worst when it comes to the IP provisions in trade deals. In earlier talks, Canadian negotiators would often advocate … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent Term Extension, TPP, TRIPS, TRIPS plus, Uncategorized | Leave a comment

Time for costly medicine monopolies to go from TPP trade talks

Source: Conversation.com |November 9, 2017 Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend. The latest plan to get the controversial trade deal up and running … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, TPP, Uncategorized | Leave a comment

This Shield of Patents Protects the World’s Best-Selling Drug

Over Humira’s lifetime, AbbVie has secured more than 100 patents to prevent anyone from attempting to copy the biologic, with $16 billion in annual sales. By Cynthia Koons Humira, a treatment for inflammatory diseases such as rheumatoid arthritis and psoriasis … Continue reading

Posted in Biologics/Biosimilars, Uncategorized | Leave a comment

Draft Pharmaceutical Policy, 2017

Source: All India Drug Action Network (AIDAN) The Department of Pharmaceuticals has circulated a Draft Pharmaceutical Policy, 2017 which can be accessed here. The draft policy identifies the following key objectives: a. Making essential drugs accessible at affordable prices to the … Continue reading

Posted in API, Biologics/Biosimilars, Evergreening, Innovation, IPR, Patent, R&D, Uncategorized | Leave a comment

No logic in extending length of patents

Granting a longer term for pharmaceutical patents will result in delays in the entry of generic versions and could adversely affect access to medicines   By Feroz Ali, Live Mint | July 28, 2017 A proposal to further extend the … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Roche vs Indian Pharma: The battle for a cheaper cancer drug

By Divya Rajagopal, The Economic Times|May 14, 2017 Let’s hark back to the Nineties. The HIV-AIDS epidemic was spreading across Africa, leaving thousands dead, in spite of the existence of anti-retroviral drugs (ARVs). The cost of the treatment, around $10,000, … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Leave a comment

Competition Commission of India pulls up Roche for anti-competitive practices

By Jyotsna Singh, Scroll | April 27, 2017 In a landmark order, the commission has initiated an investigation into the multinational pharmaceutical company’s activities. The Competition Commission of India has initiated an investigation into Swiss pharmaceutical giant Roche for unfair … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Tagged , , , | Leave a comment